within Pharmacolibrary.Drugs.ATC.N;

model N02AX02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.68,
    Cl             = 9.833333333333334e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0027,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006500000000000001,
    Tlag           = 19.8,            
    Vdp             = 0.0026,
    k12             = 1.45,
    k21             = 1.45
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02AX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tramadol is an opioid analgesic used for the management of moderate to moderately severe pain in adults. It is a centrally acting analgesic that binds to mu-opioid receptors and also inhibits the reuptake of norepinephrine and serotonin. Tramadol is widely approved and used today in clinical practice for pain management.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral dose.</p><h4>References</h4><ol><li><p>Grond, S, &amp; Sablotzki, A (2004). Clinical pharmacology of tramadol. <i>Clinical pharmacokinetics</i> 43(13) 879–923. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200443130-00004&quot;>10.2165/00003088-200443130-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15509185/&quot;>https://pubmed.ncbi.nlm.nih.gov/15509185</a></p></li><li><p>Richard, MJ, et al., &amp; McAlindon, TE (2023). Pharmaceutical treatment of osteoarthritis. <i>Osteoarthritis and cartilage</i> 31(4) 458–466. DOI:<a href=&quot;https://doi.org/10.1016/j.joca.2022.11.005&quot;>10.1016/j.joca.2022.11.005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36414224/&quot;>https://pubmed.ncbi.nlm.nih.gov/36414224</a></p></li><li><p>Lu, L, et al., &amp; Reines, SA (2020). Comparing the Pharmacokinetics of 2 Novel Intravenous Tramadol Dosing Regimens to Oral Tramadol: A Randomized 3-Arm Crossover Study. <i>Clinical pharmacology in drug development</i> 9(4) 537–546. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.746&quot;>10.1002/cpdd.746</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31610100/&quot;>https://pubmed.ncbi.nlm.nih.gov/31610100</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02AX02;
